Clinical trials: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00047021
- Testing
- sargramostim, cytarabine, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00003397
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Hematologic Malignancy, AML
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN
- Trial name
- NCT05476770
- Testing
- Tagraxofusp, Fludarabine, Cytarabine
- Where
- 31 sites in United States, Australia
- Volunteers
- 54 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase I trial to study the effectiveness of XK469R in treating patients who have refractory hematologic cancer. Drugs used in chemotherapy, such XK469R, work in different ways to stop cancer cells from dividing so they stop…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00095797
- Testing
- R(+)XK469, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00104923
- Testing
- fenretinide
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- California Cancer Consortium
Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
- Conditions
- Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01239875
- Testing
- dendritic cell vaccine therapy, cryotherapy, pneumococcal polyvalent vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, B-cell Lymphoma
- Trial name
- NCT04796688
- Testing
- Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
- Trial name
- CARTHIAE-1 (NCT05705570)
- Testing
- Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Nelson Hamerschlak
Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
This phase I trial studies the side effects and the best dose of alisertib when given together with vorinostat in treating patients with Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, or peripheral T-cell lymphoma that has come…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT01567709
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
This study is a multicenter, prospective, interventional clinical trial aimed at recruiting relapsed/refractory Ph-ALL patients at multiple stem cell transplantation centers, including the Stem Cell Transplantation Center of the…
- Trial name
- NCT06087419
- Testing
- chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin
- Volunteers
- 42 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of CPI-613 (6,8-bis[benzylthio]octanoic acid) when given together with bendamustine hydrochloride and rituximab in treating patients with B-cell non-Hodgkin lymphoma that…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT02168907
- Testing
- 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
RATIONALE: AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AR-42 in treating patients with advanced or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01129193
- Testing
- Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Amir Mortazavi
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia…
- Trial name
- ZUMA-4 (NCT02625480)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 30 sites in United States, Belgium and 9 more
- Volunteers
- 95 people
- Sponsor
- Kite, A Gilead Company
Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with human immunodeficiency virus (HIV) infection.
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT02109224
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma.
- Trial name
- ECAR01 (NCT06961669)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital